VAERS Reports #EL9265, #EN620

VAERS 1854341

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge #EL9265, #EN620

schwer

Staat: MI
Alter: 72,0
Geschlecht: M
Eingang: 09.11.2021
Impfdatum: 19.02.2021
Beginn: 26.10.2021
Tage bis Beginn: 249,0
Dosis: 2
Route/Site: UN / UN

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: nein

Activated partial thromboplastin time shortened Alanine aminotransferase increased Anion gap increased Antibody test negative Anticoagulant therapy Aspartate aminotransferase increased Base excess Basophil percentage decreased Blood albumin normal Blood alkaline phosphatase increased Blood bicarbonate normal Blood bilirubin increased Blood calcium normal Blood chloride normal Blood creatinine increased Blood gases Blood glucose increased Blood lactate dehydrogenase increased

Symptomtext

Respiratory distress. He is 60% on nonrebreather, tachycardic in the 140s, normotensive. He is placed immediately on BiPAP 10/5 and does have improvement of his oxygen saturation. He continues to be tachycardic and is given Cardizem 10 mg IV for concern of A. fib with RVR, continued on Cardizem drip, heparin and broad-spectrum antibiotics.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Respiratory distress
Hospital-Tage: -
Labordaten: Lab Results: Other Chemistry: 06-Nov-21 13:20, Brain Natriuretic Peptide Brain Natriuretic Peptide 329 [10 - 100 pg/ml] A cutoff of 100 pg/mL has been demonstrated to provide the maximal combination of sensitivity, specificity, and negative predictive value for contributing to the diagnosis of congestive heart failure (CHF). A BNP value greater than 100 pg/mL is consistent with a diagnosis of CHF in the appropriate clinical setting. Blood concentrations of natriuretic peptides may also be elevated in patients with myocardial infarction and in patients who are candidates for or are undergoing renal dialysis. 06-Nov-21 13:20, Chemistry 14 Profile Estimated GFR African American 57.43 [60.00 - 130. ml/ min] Estimated Glomerular Filtration Rate 47.46 [60.00 - 130. ml/ min] Estimated GFR Value <60 ml/min/1.73 sq meters is indicative of chronic kidney disease <15 ml/min/1.73 sq meters is indicative of kidney failure The Estimated GFR is calculated by the four variable MDRD equation. Limitations of this calculation include: Decreased accuracy for values >60 Decreased accuracy in the hospitalized/severely ill patient populations Disregard EGFR values for infants and children (should not be applied to this age group) 06-Nov-21 13:20, Magnesium Level, Serum Magnesium Level, Serum 2.4 [1.6 - 2.6 mg/dL] 06-Nov-21 13:20, Troponin I Troponin I 0.08 [0.00 - 0.03 ng/mL] Normal: <= 0.03 ng/mL Indeterminate: 0.04-0.29 ng/mL Suggestive of Myocardial Damage: >= 0.30 ng/mL 06-Nov-21 13:20, TSH With Reflex To Free T4 Thyroid Stimulating Hormone 2.225 [0.350 - 4.94 uIU/ml] ABG & VBG: 06-Nov-21 13:10, Venous Blood Gas Request *FIO2 100.0 ABG/VBG Comment Bipap 10/5 100% Other Hematology: 06-Nov-21 13:20, *Manual Differential Macrocytosis 2+ Coagulation: 06-Nov-21 13:20, D Dimer D Dimer >7650 [0 - 500 ng/mL FCU] This D-Dimer method is FDA approved for exclusion of both deep vein thrombosis (DVT) and pulmonary embolism (PE) at a cut-off value of 500 ng/mL FEU when the clinical probability of DVT or PE is low (e.g. when assessed by Wells or Modified Geneva scores). Additionally the cut-off value for PE exclusion can be age adjusted upwards for patients greater than 50 years old by multiplying the patient's age by 10 (e.g. 78 y/o patient would have an upper limit of 780 ng/mL FEU). (ref. Righini et al, JAMA2014, 311: 1117-1124). 06-Nov-21 13:20, PT Protime Protime. 13.4 [10.1 - 12.5 sec] INR 1.21 [0.80 - 1.20] Therapeutic range for DVT, PE and prophylactic use 2.0-3.0 Therapeutic range for high risk patients and mechanical heart valve patients 2.5-3.5 06-Nov-21 13:20, PTT PTT 35 [26 - 39 sec] Serology: 06-Nov-21 13:20, CRP Quantitative CRP Quantitative 76.43 [0.00 - 5.00 mg/L] CBC-Differential-Morphology: 06-Nov-21 13:20, *Manual Differential Segmented Neutrophils 69 [50 - 70 %] Lymphocytes 18 [22 - 50 %] Monocytes 12 [0 - 12 %] Eosinophils 0 [0 - 6 %] Basophils 0 [0 - 2 %] Metamyelocyte 1 [0 - 0 %] RBC Morphology Abnormal WBC Morphology Normal Large Platelets Present 06-Nov-21 13:20, CBC White Blood Cell Count 15.9 [4.5 - 11.0 K/cmm] Red Blood Cell Count 5.28 [3.90 - 5.60 M/cmm] Hemoglobin 18.3 [12.0 - 17.3 g/dL] Hematocrit 56.1 [36.0 - 53.0 %] Mean Corpuscular Volume 106.4 [80.0 - 100.0 fl] Mean Corpuscular Hemoglobin 34.7 [26.0 - 34.0 PG] Mean Corpuscular Hemoglobin Concn 32.6 [31.0 - 37.0 %] Red Cell Distribution Width 14.9 [11.5 - 14.5 %] *Platelet Count 158 [140 - 440 K/cmm] WBC and platelet count were obtained from a citrated dilution Mean Platelet Volume 8.2 [7.4 - 10.4 FL] Automated Neutrophils % 68 [ %] Automated Lymphocytes % 19 [ %] Automated Monocytes % 12 [ %] Automated Eosinophils % 0 [ %] Automated Basophils % 0 [ %] Absolute Neutrophil Count 10.9 [1.0 - 8.0 K/cmm] Absolute Lymphocyte Count 3.0 [1.0 - 5.0 K/cmm] Absolute Monocyte Count 1.9 [0.1 - 0.8 K/cmm] Blood Bank: 06-Nov-21 13:20, *ABO Rh Confirm ABO Rh Confirm Interpretation A POS 06-Nov-21 13:20, Type And Screen ABORh Interpretation A POS Antibody Screen Interpretation Negative ABSC Chemistry Panels & Profiles: 06-Nov-21 13:20, Chemistry 14 Profile Sodium Level, Serum 139 [136 - 144 mmol/L] Potassium Level, Serum 4.0 [3.6 - 5.1 mmol/L] Chloride Level, Serum 104 [101 - 111 mmol/L] Total Carbon Dioxide, Serum 14 [20 - 30 mmol/L] Blood Urea Nitrogen, Serum 27 [8 - 26 mg/dL] Creatinine Level, Serum 1.46 [0.61 - 1.24 mg/dL] Anion Gap 21 [8 - 16 mmol/L] Glucose, Serum 276 [70 - 99 mg/dL] The above reference range for glucose is appropriate for the fasting state. For random specimens, values up to 140 mg/dL are considered normal. Calcium Level, Serum 10.5 [8.4 - 10.2 mg/dL] Albumin Level, Serum 4.2 [3.5 - 5.0 g/dL] Phosphorus Level, Serum 4.4 [2.3 - 4.7 mg/dL] Bilirubin, Total 2.1 [0.3 - 1.0 mg/dL] Protein Total Level, Serum 7.8 [6.5 - 8.1 g/dL] Aspartate Aminotransferase (SGOT) 114 [15 - 41 U/L] Alanine Aminotransferase (SGPT) 100 [17 - 63 U/L] Alkaline Phosphatase, Serum 65 [41 - 150 U/L] Lactic Dehydrogenase (LDH), Serum 512 [125 - 220 IU/L] VBGs: 06-Nov-21 13:10, Venous Blood Gas Request pH. 7.320 [7.320 - 7.42] pCO2. 32.8 [41.0 - 51.0 mm Hg] pO2. 39.1 [37.0 - 43.0 mm Hg] O2 Saturation 59.1 [70.0 - 76.0 %] Actual Bicarbonate. 16.4 [ mmol/L] Hemoglobin, Total. 18.9 [13.3 - 17.1 g/dL] *Carboxyhemoglobin Saturation. 2.2 [ %] Oxygen Content. 15.7 [17.5 - 23.0 Vol %] Methemoglobin.. 1.0 [ %] Base Excess. -8.2 [0.0 - 2.0 mmol/L] V/Q study
Aktuelle Erkrankungen: unknown
Vorgeschichte: A. fib not on anticoagulation, CHF, diabetes, recently diagnosed with pulmonary hypertension presenting for sudden onset shortness of breath. Patient reports recent admission to Ascension Providence with Covid several weeks ago,
Andere Medikamente: unknown
Allergien: Iodine
Vorherige Impfungen: -